Dallah rated ‘neutral;’ target price raised to SAR 144.6

24/06/2015 Argaam

Aljazira Capital kept a “neutral” rating for Dallah Healthcare Holding Company, and set a higher target price of SAR 144.6 per share.

Dallah’s profit is expected to grow 5.4 percent to SAR 186.7 million this year, according to Aljazira. 

 

The firm based its rating and profit estimates on higher revenues expected from the company’s North Clinics expansion project.

Comments {{getCommentCount()}}

Be the first to comment

{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
{{comment.Replies.length}}
تعديل
loader Train
Report
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.